Johanna CPA - Poseida Therapeutics Chief Officer
| PSTXDelisted Stock | USD 9.50 0.08 0.84% |
Insider
Johanna CPA is Chief Officer of Poseida Therapeutics
| Age | 37 |
| Phone | 858 779 3100 |
| Web | https://poseida.com |
Poseida Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1311) % which means that it has lost $0.1311 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5763) %, meaning that it created substantial loss on money invested by shareholders. Poseida Therapeutics' management efficiency ratios could be used to measure how well Poseida Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Poseida Therapeutics currently holds 85.42 M in liabilities with Debt to Equity (D/E) ratio of 1.39, which is about average as compared to similar companies. Poseida Therapeutics has a current ratio of 3.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Poseida Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Eric Rojas | Stoke Therapeutics | N/A | |
| Paul MD | AN2 Therapeutics | 54 | |
| Morgan Conn | Pharvaris BV | 55 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Walter Reiher | Revolution Medicines | N/A | |
| Wim Souverijns | Pharvaris BV | 54 | |
| Tracy Zimmermann | Generation Bio Co | 54 | |
| Kenneth JD | Century Therapeutics | N/A | |
| Caroline Godfrey | PepGen | N/A | |
| Mark Wallet | Century Therapeutics | N/A | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| Anne Lesage | Pharvaris BV | 64 | |
| Path FRCP | Revolution Medicines | 61 | |
| Narayan Prabhu | Reviva Pharmaceuticals Holdings | 53 | |
| Patrick Amstutz | Molecular Partners AG | 50 | |
| Hal MD | Pliant Therapeutics | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Gene Kim | Dyne Therapeutics | 47 | |
| FACC MD | Cytokinetics | 58 | |
| Matthew Stanton | Generation Bio Co | 52 | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 |
Poseida Therapeutics Leadership Team
Elected by the shareholders, the Poseida Therapeutics' board of directors comprises two types of representatives: Poseida Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Poseida. The board's role is to monitor Poseida Therapeutics' management team and ensure that shareholders' interests are well served. Poseida Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Poseida Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Loren Wagner, Senior Operations | ||
| Sarah Thailing, Senior IR | ||
| JD Esq, Chief Counsel | ||
| Johanna CPA, Chief Officer | ||
| Kristin Martin, Chief Officer | ||
| Alexander Chapman, Senior Communications | ||
| Karen MBA, Senior Development | ||
| Brent Warner, President Therapy | ||
| Mark JD, Executive Board | ||
| Devon Shedlock, Chief Therapy | ||
| Lisa Portale, Senior Affairs | ||
| Kristin Yarema, CEO President | ||
| Dr JD, Senior Counsel |
Poseida Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Poseida Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.40) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 777.81 M | ||||
| Shares Outstanding | 97.47 M | ||||
| Shares Owned By Insiders | 27.64 % | ||||
| Shares Owned By Institutions | 58.44 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | 214.00 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Poseida Stock
If you are still planning to invest in Poseida Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Poseida Therapeutics' history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |